ArticleFrontiers in reproductive health2026
Influence of corifollitropin alfa on embryo morphokinetics and fertility treatment outcome.
Article in Frontiers in reproductive health, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: Corifollitropin alfa (CFA) is a long-acting recombinant follicle-stimulating hormone that reduces injection burden during controlled ovarian stimulation (COS). While its clinical efficacy has been demonstrated, its potential influence on early embryo development assessed by time-lapse morphokinetics remains insufficiently explored. Methods: This retrospective cohort study analyzed embryos derived from COS using either CFA or daily follitropin β. A total of 561 embryos from 99 CFA-stimulated patients and 3,116 embryos from 481 follitropin β-stimulated patients were included. Embryos were cultured in a time-lapse incubator, and morphokinetic parameters including pronuclear fading (tPNf) and early cleavage stages from t2 to t8 were recorded. Linear mixed-effects models were applied to account for repeated measurements per patient. Clinical outcomes including fertilization, biochemical, clinical and live birth rates were compared between groups. Results: Patients receiving CFA were older and showed lower anti-Müllerian hormone levels and higher baseline FSH concentrations, indicating a reduced ovarian reserve. No significant differences were observed between groups in morphokinetic parameters, including cleavage timings (t2-t8), cleavage synchronicity, or early developmental progression (all Conclusions: Controlled ovarian stimulation with CFA does not appear to affect early embryo morphokinetics as assessed by time-lapse imaging. Despite differences in baseline patient characteristics, CFA was associated with comparable embryo developmental dynamics and live birth outcomes compared with daily follitropin
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.